Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30670233 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1GAANQO1MEN1 | |
| SCHEMBL4711831 | 0.79 | TDP1 (0.49) | KDM4EALDH1A1GAANQO1MEN1 | |
| SCHEMBL271403 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1GAANQO1MEN1 | |
| SCHEMBL29407440 | 0.77 | ALDH1A1 (0.33) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL10847356 | 0.76 | CA12 (0.44) | KDM4EALDH1A1GAANQO1MEN1 | |
| SCHEMBL4619990 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1GAANQO1MEN1 | |
| SCHEMBL6194825 | 0.73 | MAOA (0.50) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL5969266 | 0.72 | MAOA (0.48) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL16538009 | 0.71 | MAOA (0.43) | KDM4EALDH1A1GAANQO1MEN1 | |
| SCHEMBL18330473 | 0.71 | KDM4E (0.45) | KDM4EALDH1A1GAANQO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469864-B2 | Reversible natural product glycosyltransferase-catalyzed reactions, compounds and related methods | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-10-18 | — | — | US | claimed |
| US-20150141294-A1 | REVERSIBLE NATURAL PRODUCT GLYCOSYLTRANSFERASE-CATALYZED REACTIONS, COMPOUNDS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | claimed |
| US-8841092-B2 | Reversible natural product glycosyltransferase-catalyzed reactions, compounds and related methods | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-23 | — | — | US | claimed |
| US-20130004979-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-03 | — | — | US | claimed |
| US-8093028-B2 | Engineered glycosyltransferases with expanded substrate specificity | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-01-10 | — | — | US | claimed |
| US-20110306074-A1 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-12-15 | — | — | US | claimed |
| US-20090275485-A1 | Reversible Natural Product Glycosyltransferase-Catalyzed Reactions, Compounds and Related Methods | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-11-05 | — | — | US | claimed |
| US-20090181854-A1 | Engineered Glycosyltransferases With Expanded Substrate Specificity | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-16 | — | — | US | claimed |
| WO-2009015268-A2 | ENGINEERED GLYCOSYLTRANSFERASES WITH EXPANDED SUBSTRATE SPECIFICITY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | WO | claimed |
| WO-2008028050-A2 | REVERSIBLE NATURAL PRODUCT GLYCOSYLTRANSFERASE-CATALYZED REACTIONS, COMPOUNDS AND RELATED METHODS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-06 | — | — | WO | claimed |
| US-20050266523-A1 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-12-01 | — | — | US | claimed |
| US-6884604-B2 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-26 | — | — | US | claimed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | claimed |
| WO-2002079150-A2 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2025122699-A1 | CDC7 INHIBITOR COMBINATIONAL THERAPY | Lin Bioscience, Inc. (TW) | 2025-06-12 | — | — | WO | disclosed |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | Lin Bioscience, Inc. (TW) | 2025-03-20 | — | — | US | disclosed |
| US-20240423951-A1 | CDC7 KINASE INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2024-12-26 | — | — | US | disclosed |
| US-20040259228-A1 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-23 | — | — | US | disclosed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | disclosed |
| WO-2002079150-A2 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423951-A1 | CDC7 KINASE INHIBITORS AND USES THEREOF | CDC7, CDC37, CDCA2 | KDM4E 1980/4885ALDH1A1 3901/4885GAA 2086/4885 |
| US-20090275485-A1 | Reversible Natural Product Glycosyltransferase-Catalyzed Reactions, Compounds and Related Methods | UGGT1, ENGASE, CSGALNACT1 | KDM4E 3370/4885ALDH1A1 1249/4885GAA 210/4885 |
| US-20250090495-A1 | CDC7 Inhibitor Combinational Therapy | CDC7, MCM7, BOD1L1 | KDM4E 927/4885ALDH1A1 4000/4885GAA 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.